Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach

Objective: We suggested cervical cancer screening strategies for women living with HIV (WLHIV) by comparing their precancer risks to general population women, and then compared our suggestions with current Centers for Disease Control and Prevention (CDC) guidelines. Design: We compared risks of biopsy-confirmed cervical high-grade squamous intraepithelial neoplasia or worse (bHSIL+), calculated among WLHIV in the Women's Interagency HIV Study, to ‘risk benchmarks’ for specific management strategies in the general population. Methods: We applied parametric survival models among 2423 WLHIV with negative or atypical squamous cell of undetermined significance (ASC-US) cytology during 2000–2015. Separately, we synthesized published general population bHSIL+ risks to generate 3-year risk benchmarks for a 3-year return (after negative cytology, i.e. ‘rescreening threshold’), a 6–12-month return (after ASC-US), and immediate colposcopy [after low-grade squamous intraepithelial lesion (LSIL)]. Results: Average 3-year bHSIL+ risks among general population women (’risk benchmarks’) were 0.69% for a 3-year return (after negative cytology), 8.8% for a 6–12-month return (after ASC-US), and 14.4% for colposcopy (after LSIL). Most CDC guidelines for WLHIV were supported by comparing risks in WLHIV to these benchmarks, including a 3-year return with CD4+ greater than 500 cells/&mgr;l and after either three negative cytology tests or a negative cytology/oncogenic human papillomavirus cotest (all 3-year risks⩽1.3%); a 1-year return after negative cytology with either positive oncogenic human papillomavirus cotest (1-year risk = 1.0%) or CD4+ cell count less than 500 cells/&mgr;l (1-year risk = 1.1%); and a 6–12-month return after ASC-US (3-year risk = 8.2% if CD4+ cell count at least 500 cells/&mgr;l; 10.4% if CD4+ cell count = 350–499 cells/&mgr;l). Other suggestions differed modestly from current guidelines, including colposcopy (vs. 6–12 month return) for WLHIV with ASC-US and CD4+ cell count less than 350 cells/&mgr;l (3-year risk = 16.4%) and a lengthened 2-year (vs. 1-year) interval after negative cytology with CD4+ cell count at least 500 cells/&mgr;l (2-year risk = 0.98%). Conclusions: Current cervical cancer screening guidelines for WLHIV are largely appropriate. CD4+ cell count may inform risk-tailored strategies.

[1]  J. Cuzick,et al.  Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[2]  K. Anastos,et al.  Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Strickler,et al.  Incidence of cervical precancers among HIV-seropositive women. , 2015, American journal of obstetrics and gynecology.

[4]  R. Pfeiffer,et al.  Excess cancers among HIV-infected people in the United States. , 2015, Journal of the National Cancer Institute.

[5]  Mardge H. Cohen,et al.  Long-term cumulative detection of human papillomavirus among HIV seropositive women , 2014, AIDS.

[6]  J. Palefsky,et al.  Cervical human papillomavirus testing to triage borderline abnormal pap tests in HIV-coinfected women. , 2014, AIDS.

[7]  H. Minkoff,et al.  Long‐term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse after abnormal cytology: Impact of HIV infection , 2014, International journal of cancer.

[8]  R. Pfeiffer,et al.  Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States , 2014, AIDS.

[9]  D. Costagliola,et al.  Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Robert P Berkowitz,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[11]  Richard D Moore,et al.  Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study , 2013, Journal of acquired immune deficiency syndromes.

[12]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results , 2013, Journal of lower genital tract disease.

[13]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive , 2013, Journal of lower genital tract disease.

[14]  M. Schiffman,et al.  Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines , 2013, Journal of lower genital tract disease.

[15]  M. Henry,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2012, Archives of pathology & laboratory medicine.

[16]  Mardge H. Cohen,et al.  Negative Predictive Value of Pap Testing: Implications for Screening Intervals for Women With Human Immunodeficiency Virus , 2012, Obstetrics and gynecology.

[17]  Richard D Moore,et al.  U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 , 2012, Annals of Internal Medicine.

[18]  David R. Scott,et al.  Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Anastos,et al.  Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. , 2012, JAMA.

[20]  Evan R. Myers,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer , 2012, Journal of lower genital tract disease.

[21]  V. Moyer,et al.  Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[22]  S. Rosen,et al.  Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review , 2011, PLoS medicine.

[23]  J. Sterne,et al.  Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study , 2010, AIDS.

[24]  J. Palefsky,et al.  Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. , 2010, The Journal of infectious diseases.

[25]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[26]  N. Hessol,et al.  Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. , 2009, Journal of women's health.

[27]  N. Hessol,et al.  Long‐term incidence of cervical cancer in women with human immunodeficiency virus , 2009, Cancer.

[28]  R. Burk,et al.  Squamous Cervical Lesions in Women With Human Immunodeficiency Virus: Long-Term Follow-up , 2008, Obstetrics and gynecology.

[29]  Diane Solomon,et al.  Risk assessment to guide the prevention of cervical cancer. , 2007, American journal of obstetrics and gynecology.

[30]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[31]  H. Greenberg,et al.  Immunity and correlates of protection for rotavirus vaccines. , 2006, Vaccine.

[32]  M. Young,et al.  The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.

[33]  K. Anastos,et al.  Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. , 2005, JAMA.

[34]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[35]  A. Moscicki,et al.  Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. , 2004, The Journal of infectious diseases.

[36]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[37]  David R. Scott,et al.  Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible , 2002, Journal of Clinical Microbiology.

[38]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[39]  M. Henry,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2013 .

[40]  L. Kalish,et al.  The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.